PARP1 and prostate carcinoma: In addition, Yap at al. reported the activation of PARP and procaspases (3, 7, 8, and 9) in the prostate cancer cell line, PC-3, as their cleaved products increased upon treatment with different concentrations of γ-tocotrienol.